Karo Pharma AB  

(Public, STO:KARO)   Watch this stock  
Find more results for KARO
-1.20 (-3.35%)
Oct 28 - Close
STO real-time data - Disclaimer
Currency in SEK
Range 34.10 - 36.00
52 week 21.48 - 44.00
Open 36.00
Vol / Avg. 178,885.00/160,844.00
Mkt cap 2.21B
P/E     -
Div/yield     -
EPS -1.17
Shares 63.60M
Beta     -
Inst. own     -
Oct 27, 2016
Q3 2016 Karo Pharma AB Earnings Release
Oct 27, 2016
Q3 2016 Karo Pharma AB Earnings Call (Swedish)

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -3.43% -113.16%
Operating margin -1.72% -108.35%
EBITD margin - -99.33%
Return on average assets -1.70% -22.24%
Return on average equity -2.30% -38.40%
Employees 64 -
CDP Score - -


Halsovagen 7, plan 8
HUDDINGE, 141 57
+46-8-6086000 (Phone)
+46-8-7748261 (Fax)

Website links


Karo Pharma AB, formerly known as Karo Bio AB, is a Sweden-based biopharmaceutical company engaged in the research and development of drugs based on the nuclear receptors. The Company’s pipeline comprises three projects: Estrogen Receptor Beta (ERbeta) cancer, a platform, which focuses on the development of ERbeta in cancer treatment; ERbeta multiple sclerosis (MS), which specializes in the autoimmune disease MS treatment; and Related Orphan Receptor Gamma (RORgamma), which is responsible for the nuclear receptors application in treatment of autoimmune disease, such as rheumatoid arthritis and psoriasis. The Company collaborates with Pfizer, 4D Science, and Merck, among others. Its trademarks portfolio includes Karo Bio, BioKey, BioKey Assay and Molecular Braille. The Company operates Karo Bio Research AB, Karo Bio Discovery AB, Kommanditbolaget Odenplan Fastigheter, Tanomed AB and MedCore AB as subsidiaries.

Officers and directors

Anders Lonner Executive Chairman of the Board of Directors
Age: 71
Maria Sjoberg Chief Executive Officer, Head of Preclinical Research and Development
Age: 52
Henrik Palm Chief Financial Officer, Vice President
Age: 58
Thomas Hedner Independent Director
Age: 67
Per-Anders Johansson Independent Director
Age: 62
Jean Lycke Independent Director
Age: 52